Adjuvant Radiotherapy after Endoscopic Resection for Stage I Esophageal Carcinoma: Results from a Pilot Study
X. Yang,Y. Men,J. Wang,J. Kang,X. Sun,M. Zhao,S. Sun,M. Yuan,Y. Bao,Z. Ma,G. Wang,Z. Hui
DOI: https://doi.org/10.1016/j.ijrobp.2020.07.1843
2020-01-01
Abstract:To evaluate the safety and efficacy of adjuvant radiotherapy after endoscopic resection for stage I esophageal carcinoma with high risk factors. A pilot study of adjuvant radiotherapy for endoscopically resected pT1 esophageal carcinoma was carried out in our single institution. The main inclusion criteria included: (1) Histologically proven thoracic esophageal carcinoma; (2) Clinical staging T1N0M0 patients; (3) pT1 stage with high risk factors (submucosal or lymphovascular invasion) based on endoscopically resected specimen. Enrolled patients received radiotherapy, with or without concurrent chemotherapy. The total radiation dose was 50-60 Gy in 25-30 fractions. The common acute toxicities, dysphagia at last follow-up, local control rate (LCR), overall survival (OS), disease free survival (DFS) and failure pattern were analyzed. From July 2011 to April 2019, 31 consecutive patients were enrolled. There were 25 (80.6%) males and six (19.4%) females. The median age was 62 (49-78) years old. Thirty (96.8%) patients were squamous cell carcinoma, and one (3.2%) was adenocarcinoma. The number of patients with tumor of poor, moderate, moderate-poor and high differentiation were 12 (38.7%), 13 (41.9%), 2 (6.5%) and 4 (12.9%), respectively. Fifteen (48.4%) patients were diagnosed with lymphovascular invasion, and 26 (83.9%) were with submucosal invasion with a median invasion depth of 650 (50-1550) μm. All patients received complete endoscopic submucosal dissection. All patients completed adjuvant radiotherapy as schedule, except one received 44 Gy due to refusal. The common acute toxicities included esophagitis (Grade 1-2, 67.7%; Grade 3, 12.9%), radiation pneumonitis (Grade 1, 48.4%), leucopenia (Grade 1-2, 54.8%), and thrombocytopenia (Grade 1-2, 12.9%). No Grade 4-5 acute toxicities were observed. Six patients (19.4%) received chemotherapy concurrently with radiotherapy. No statistically significant difference of acute toxicities was observed between patients who received concurrent chemotherapy or not. The median follow-up time was 19.7 (95% CI, 12.5-26.9) months. At the last follow-up, 28 (90.5%) patients were able to eat regular diet and only one needed liquid diet. The LCR was 100.0%. Relapse was found in three patients, which was all with distant metastasis, including two with synchronous regional lymph node recurrence. The 1-, 3- and 5-year OS were 100.0%, 88.9%, and 74.1%, respectively. And the 1-, 3- and 5-year DFS were 100.0%, 74.1% and 74.1%, respectively. The median OS and DFS were not reached. In univariate analysis, only tumor size was prognostic factor for OS (p = 0.014). No independent prognostic factor was found for OS and DFS. Adjuvant radiotherapy after endoscopic resection is a safe and efficient supplement treatment for stage I esophageal carcinoma with high risk factors. Chemoradiotherapy may be a more reasonable adjuvant treatment based on the failure pattern.